PD-L1 IHC: Definition, Uses, and Clinical Overview

PD-L1 IHC Introduction (What it is)

PD-L1 IHC is a lab test that looks for the PD-L1 protein in a cancer tissue sample.
It uses immunohistochemistry (IHC), a staining method that makes certain proteins visible under a microscope.
It is commonly used in oncology to help guide immunotherapy decisions and to describe tumor biology.

Why PD-L1 IHC used (Purpose / benefits)

PD-L1 IHC is used as a biomarker test—a test that measures a feature of a tumor that may be clinically meaningful. PD-L1 (programmed death-ligand 1) is a protein that can be present on tumor cells and/or immune cells within the tumor environment. In some cancers, PD-L1 expression is associated with how likely a tumor is to respond to certain immune checkpoint inhibitors (immunotherapy drugs that target the PD-1/PD-L1 pathway).

In practical terms, PD-L1 IHC helps clinicians address common oncology problems such as:

• Treatment selection: For some cancer types and drug indications, PD-L1 IHC results may be used to determine whether a patient is eligible for a specific immunotherapy, or whether immunotherapy might be considered as part of a regimen.
• Risk–benefit discussion: A PD-L1 result can contribute to conversations about the potential benefit of immunotherapy compared with other options. It is not a guarantee of response or non-response.
• Standardization of care: Many oncology pathways incorporate biomarker testing so that treatment planning is based on tumor characteristics rather than cancer site alone.
• Clinical trial matching: Trials may require PD-L1 testing to enroll participants or to assign treatment groups.

PD-L1 IHC does not diagnose cancer by itself. Instead, it is typically ordered after cancer is diagnosed, as part of a broader workup that can include histology (the tumor type under the microscope), staging tests, and other biomarkers.

Indications (When oncology clinicians use it)

PD-L1 IHC may be ordered in scenarios such as:

• Newly diagnosed or recurrent advanced/metastatic solid tumors where immunotherapy is being considered (varies by cancer type and stage)
• Non-small cell lung cancer (NSCLC) biomarker workup alongside other common molecular tests (depends on local practice and guidelines)
• Head and neck squamous cell carcinoma, urothelial carcinoma, triple-negative breast cancer, and certain gastroesophageal and gynecologic cancers where PD-L1 status may affect available options (varies by clinician and case)
• When a clinician is considering first-line vs later-line systemic therapy choices and wants additional tumor profiling
• When evaluating a new biopsy from progression or recurrence, where biomarker status may have changed over time

Contraindications / when it’s NOT ideal

PD-L1 IHC is a tissue-based laboratory test, so “contraindications” are usually about whether the available specimen can support accurate testing. Situations where PD-L1 IHC may be less suitable or may require an alternative approach include:

• Insufficient tumor tissue (too little tumor present on the slide, or too few viable tumor cells)
• Poor specimen quality due to processing issues (for example, prolonged time before fixation, suboptimal fixation, or heavy crush artifact)
• Decalcified bone specimens, where some decalcification methods can reduce antigen detectability and affect IHC reliability (impact varies by method)
• Old or exhausted blocks when multiple tests have already used most of the tissue
• Cases where another biomarker is more immediately actionable for a specific cancer (for example, certain targetable driver alterations), while PD-L1 may still be considered depending on context
• Situations where a clinician may prefer repeat biopsy or a different sample site because PD-L1 can be heterogeneous (unevenly expressed within or between tumor sites)

If PD-L1 IHC is not feasible, clinicians may consider using a different specimen (if available), repeating biopsy when appropriate, or relying on other clinical and biomarker information.

How it works (Mechanism / physiology)

PD-L1 IHC works by detecting PD-L1 protein in tumor tissue using antibodies designed to bind specifically to PD-L1. After the antibody binds, additional reagents produce a visible stain that a pathologist can evaluate under a microscope.

Key biology and clinical context:

• The PD-1/PD-L1 pathway: PD-1 is a receptor on certain immune cells (including T cells). PD-L1 on tumor cells and/or immune cells can interact with PD-1 and contribute to reduced immune activity against the tumor. This pathway is one reason some cancers can evade immune detection.
• Tumor microenvironment: PD-L1 IHC does not measure only the tumor cells in isolation. Depending on the scoring system, it may also incorporate PD-L1 staining on immune cells within and around the tumor.
• What the test result represents: PD-L1 IHC is a snapshot of PD-L1 expression in the sampled tissue at that time. PD-L1 expression can vary across tumor areas and can change with time or treatment.

Onset/duration and reversibility: PD-L1 IHC is not a treatment, so “onset” and “duration” do not apply the way they would for a drug. The closest relevant concept is that the result reflects the sampled lesion and may not permanently represent the tumor’s biology over the entire course of illness.

PD-L1 IHC Procedure overview (How it’s applied)

PD-L1 IHC is best understood as a test within a diagnostic and treatment-planning workflow, rather than a standalone procedure performed on a patient in real time. A typical high-level sequence may look like this:

1. Evaluation/exam: Symptoms, physical exam, and medical history lead to suspicion or confirmation of cancer.
2. Imaging/biopsy/labs: Imaging helps identify a lesion, and a biopsy (or surgical specimen) provides tissue for diagnosis. Blood tests may be done for overall health assessment.
3. Pathology diagnosis: A pathologist confirms the cancer type and subtype using routine microscopy and basic stains.
4. Staging (extent of disease): Imaging and pathology findings are combined to determine stage (varies by cancer type).
5. Biomarker testing: PD-L1 IHC may be ordered along with other tests (for example, molecular profiling). The lab prepares tissue sections and performs PD-L1 staining.
6. Scoring and reporting: A pathologist reports PD-L1 expression using a defined scoring method appropriate for the cancer type and intended therapy.
7. Treatment planning: The oncology team integrates PD-L1 results with stage, performance status, comorbidities, other biomarkers, and patient goals.
8. Response assessment and follow-up: If systemic therapy is given, follow-up usually includes clinical visits, labs, and imaging. PD-L1 IHC is not routinely repeated unless there is a clinical reason to re-biopsy (varies by clinician and case).
9. Survivorship/supportive care: Regardless of therapy choice, supportive care and survivorship planning address symptoms, function, and quality of life.

From a patient perspective, the most “hands-on” part is usually the biopsy (or surgery) that provides the tissue; PD-L1 IHC itself is performed in the laboratory on that specimen.

Types / variations

PD-L1 IHC has important variations that can affect how results are interpreted. Common categories include:

• Different antibody clones and platforms: Multiple PD-L1 antibodies exist, and labs may use different validated assays. Some are developed as “companion diagnostics” linked to specific drug indications, while others may be validated as laboratory-developed tests. Interchangeability can vary by setting.
• Different scoring systems:
• TPS (Tumor Proportion Score): Focuses on the percentage of tumor cells with PD-L1 staining. Often discussed in lung cancer contexts.
• CPS (Combined Positive Score): Incorporates PD-L1 staining on tumor cells and certain immune cells relative to tumor cell number. Often used in several gastrointestinal and head and neck settings.
• Immune cell (IC) scoring or similar approaches: In some cancers, the emphasis may be on PD-L1 expression in immune cells within the tumor area.
• Specimen types: Testing may be performed on core needle biopsies, endoscopic biopsies, surgical resections, or sometimes cell blocks from cytology specimens (feasibility varies by lab and sample quality).
• Disease context: PD-L1 IHC is primarily used in solid tumors. It is not a universal test across all hematologic malignancies, though immunophenotyping by IHC is common in hematopathology for other markers.
• Care settings: Ordering and interpretation may occur in inpatient or outpatient oncology, but the laboratory workflow is similar; turnaround time and reflex testing practices vary by institution.

Because of these variations, PD-L1 IHC results are usually interpreted in the context of the specific assay and scoring method used, as stated in the pathology report.

Pros and cons

Pros:

• Helps characterize tumor–immune biology using widely available pathology techniques
• May support eligibility decisions for certain immunotherapy indications (varies by cancer type and stage)
• Can be performed on routine formalin-fixed, paraffin-embedded tissue in many labs
• Integrates into standard pathology reporting and multidisciplinary treatment planning
• May help clinical trial matching when PD-L1 status is required

Cons:

• Not a perfect predictor: PD-L1–positive tumors may not respond, and PD-L1–negative tumors may still respond (varies by cancer type)
• Results can vary with specimen handling, assay choice, and scoring system
• Tumor heterogeneity can lead to sampling differences between biopsy sites or over time
• Limited by tissue quantity; additional biomarker tests may compete for the same sample
• Interpretation requires training and consistency; borderline cases can be challenging

Aftercare & longevity

Because PD-L1 IHC is a laboratory test, “aftercare” usually relates to what happens after the biopsy and how the result is used over time.

What can affect the usefulness and “longevity” of a PD-L1 IHC result includes:

• Cancer type and stage: How PD-L1 is used in decision-making varies by cancer and by whether disease is early-stage, locally advanced, or metastatic.
• Tumor biology and heterogeneity: PD-L1 expression may differ across tumor regions and between primary and metastatic sites. A single biopsy may not represent every lesion.
• Treatment history: Prior therapies (including radiation or systemic therapy) may be associated with changes in the tumor microenvironment; whether retesting is helpful varies by clinician and case.
• Quality of the original specimen: Good fixation and adequate tumor content support more reliable testing and may reduce the need for repeat sampling.
• Follow-up and supportive care: Regardless of PD-L1 status, outcomes are influenced by overall treatment strategy, management of side effects, rehabilitation needs, and the ability to continue planned care.

If disease status changes or a new biopsy is obtained for clinical reasons, clinicians may consider whether repeating biomarkers (including PD-L1) is appropriate in that new context.

Alternatives / comparisons

PD-L1 IHC is one tool among many used to guide oncology care. Alternatives and complementary approaches include:

• Other predictive biomarkers for immunotherapy:
• MSI/MMR testing (microsatellite instability / mismatch repair deficiency) is relevant in several cancers and may predict benefit from certain immunotherapies in some settings.
• Tumor mutational burden (TMB) may be assessed in some cases, often via genomic testing; its role varies by cancer type and by local practice.
• Gene expression–based immune signatures may be used in research or select clinical contexts, but availability varies.
• Broader molecular profiling (NGS): Next-generation sequencing can identify driver mutations or fusions that may point toward targeted therapies. In some cancers, targeted options may take priority in sequencing treatment, while immunotherapy decisions may still incorporate PD-L1.
• Clinical factors and standard staging: For many patients, performance status, organ function, comorbidities, symptoms, and disease burden strongly influence treatment selection—sometimes more than any single biomarker.
• Observation/active surveillance (where appropriate): In select cancers and stages, careful monitoring may be part of management. PD-L1 IHC generally does not replace staging and risk assessment used to choose observation.
• Local therapies vs systemic therapy: Surgery and radiation are typically chosen based on stage, anatomy, and goals of care. PD-L1 IHC is more often tied to systemic therapy planning than to local therapy decisions, though multidisciplinary planning can integrate all information.
• Clinical trials: Trials may offer access to new combinations or new biomarkers. PD-L1 IHC may be required, optional, or part of exploratory research depending on the study.

Overall, PD-L1 IHC is best viewed as one component of a larger clinical picture rather than a standalone decision-maker.

PD-L1 IHC Common questions (FAQ)

Q: Does PD-L1 IHC diagnose cancer?
No. PD-L1 IHC does not tell whether a person has cancer by itself. It is usually performed after a cancer diagnosis to help guide treatment planning, often related to immunotherapy.

Q: Is PD-L1 IHC painful?
The staining test is performed on tissue in a laboratory and does not cause pain. Any discomfort is typically related to how the tissue was obtained (for example, a needle biopsy or surgery), and that experience varies by procedure and site.

Q: Will I need anesthesia for PD-L1 IHC testing?
PD-L1 IHC itself does not require anesthesia. Anesthesia or sedation may be used for the biopsy or procedure that collects tissue, depending on the location of the tumor and the planned approach.

Q: How long does PD-L1 IHC take to get results?
Turnaround time varies by laboratory workflow, whether the test is done on-site or sent out, and whether additional biomarker tests are ordered at the same time. Your care team typically reviews results once pathology reporting is complete and integrated with other findings.

Q: What does a “positive” or “high” PD-L1 result mean?
It generally means PD-L1 was detected above a defined threshold using a specific scoring method. Depending on the cancer type and treatment setting, this may support the use of certain immunotherapy options, but it does not guarantee a response.

Q: What if my PD-L1 result is negative—does that mean immunotherapy won’t work?
Not necessarily. Some patients with low or negative PD-L1 by IHC can still respond to immunotherapy, and some PD-L1–positive tumors do not respond. Treatment decisions typically consider PD-L1 along with stage, other biomarkers, and overall health.

Q: Are there side effects from PD-L1 IHC?
The test itself has no direct side effects because it is done on a tissue sample. Potential risks relate to the biopsy or surgery used to obtain tissue, such as soreness, bruising, bleeding, or infection risk, which vary by procedure and individual factors.

Q: How much does PD-L1 IHC cost?
Costs vary widely based on country, health system, insurance coverage, whether the lab is in-network, and whether PD-L1 is bundled with other pathology or molecular tests. Billing may also differ depending on whether the assay is a specific companion diagnostic or another validated method.

Q: Can PD-L1 IHC affect fertility or pregnancy?
The PD-L1 IHC test does not affect fertility because it is performed on tissue outside the body. However, treatments considered after biomarker testing (including some systemic therapies) can have fertility or pregnancy implications, and those considerations are typically addressed during treatment planning.

Q: Will I need repeat PD-L1 testing later?
Sometimes, but not always. Repeat testing may be considered if a new biopsy is done for clinical reasons (such as progression or recurrence) or if the original sample was limited; practices vary by cancer type and by clinician and case.